相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Nanotherapeutics in autophagy: a paradigm shift in cancer treatment
Shloka Negi et al.
DRUG DELIVERY AND TRANSLATIONAL RESEARCH (2022)
Triple-Negative Breast Cancer: A Brief Review About Epidemiology, Risk Factors, Signaling Pathways, Treatment and Role of Artificial Intelligence
Nahlah Makki Almansour
FRONTIERS IN MOLECULAR BIOSCIENCES (2022)
Exosomes as Emerging Drug Delivery and Diagnostic Modality for Breast Cancer: Recent Advances in Isolation and Application
Dulla Naveen Kumar et al.
CANCERS (2022)
Anacardic acid encapsulated solid lipid nanoparticles forStaphylococcus aureusbiofilm therapy: chitosan and DNase coating improves antimicrobial activity
Md Meraj Anjum et al.
DRUG DELIVERY AND TRANSLATIONAL RESEARCH (2021)
A Conceptual Analysis of Solid Self-emulsifying Drug Delivery System and its Associate Patents for the Treatment of Cancer
Neeraj Singh et al.
RECENT PATENTS ON NANOTECHNOLOGY (2021)
Enhanced antitumor efficacy of lapachol-loaded nanoemulsion in breast cancer tumor model
Sued Eustaquio Mendes Miranda et al.
BIOMEDICINE & PHARMACOTHERAPY (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Encapsulating Halofuginone Hydrobromide in TPGS Polymeric Micelles Enhances Efficacy Against Triple-Negative Breast Cancer Cells
Runan Zuo et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2021)
Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects
Remy Thomas et al.
FRONTIERS IN ONCOLOGY (2021)
Triphenylphosphonium functionalized Ficus religiosa L. extract loaded nanoparticles improve the mitochondrial function in oxidative stress induced diabetes
Priyanka Karunanidhi et al.
AAPS PHARMSCITECH (2021)
Carbon nanotubes (CNT)-loaded ginsenosides Rb3 suppresses the PD-1/PD-L1 pathway in triple-negative breast cancer
Xiao Luo et al.
Aging-US (2021)
Inhibitors of immune checkpoints-PD-1, PD-L1, CTLA-4-new opportunities for cancer patients and a new challenge for internists and general practitioners
Marek Z. Wojtukiewicz et al.
CANCER AND METASTASIS REVIEWS (2021)
Regulation of cancer stem cells in triple negative breast cancer
Norman Fultang et al.
CANCER DRUG RESISTANCE (2021)
Targeted Oral Delivery of Paclitaxel Using Colostrum-Derived Exosomes
Raghuram Kandimalla et al.
CANCERS (2021)
Polymeric Nanoparticles for Breast Cancer Therapy: A Comprehensive Review
Ikmeet Kaur Grewal et al.
BIOINTERFACE RESEARCH IN APPLIED CHEMISTRY (2021)
DNase-I functionalization of ciprofloxacin-loaded chitosan nanoparticles overcomes the biofilm-mediated resistance of Pseudomonas aeruginosa
Krishna Kumar Patel et al.
APPLIED NANOSCIENCE (2020)
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
Peter Schmid et al.
LANCET ONCOLOGY (2020)
Delivery of Apoptosis-inducing Piperine to Triple-negative Breast Cancer Cells via Co-polymeric Nanoparticles
Javad Ghassemi Rad et al.
ANTICANCER RESEARCH (2020)
TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer
Brian D. Lehmann et al.
CLINICAL CANCER RESEARCH (2020)
A phase I study of an oral selective gamma secretase (GS) inhibitor RO4929097 in combination with neoadjuvant paclitaxel and carboplatin in triple negative breast cancer
Sagar Sardesai et al.
INVESTIGATIONAL NEW DRUGS (2020)
CD44 receptor targeted 'smart' multi-walled carbon nanotubes for synergistic therapy of triple-negative breast cancer
Nidhi Jain Singhai et al.
COLLOID AND INTERFACE SCIENCE COMMUNICATIONS (2020)
Feasibility of real-time serial comprehensive tumor analytics: Pilot study of olaparib and durvalumab in metastatic triple negative breast cancer (mTNBC).
Allen Li et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Phase II trial of bicalutamide in combination with palbociclib for the treatment of androgen receptor (+) metastatic breast cancer.
Ayca Gucalp et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
A phase Ib/II study of eribulin (ERI) plus pembrolizumab (PEMBRO) in metastatic triple-negative breast cancer (mTNBC) (ENHANCE 1).
Sara M. Tolaney et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Glycosylated one-step PAMAM dendrimers loaded with methotrexate for target therapy in breast cancer cells MDA-MB-231
Sergio Andres Torres-Perez et al.
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY (2020)
Triple-Negative Breast Cancer: A Review of Conventional and Advanced Therapeutic Strategies
Mauricio A. Medina et al.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2020)
Docetaxel-loaded solid lipid nanoparticles prevent tumor growth and lung metastasis of 4T1 murine mammary carcinoma cells
Marcia Cristina Oliveira da Rocha et al.
JOURNAL OF NANOBIOTECHNOLOGY (2020)
Antitumor and Anti-Metastatic Effects of Citral-Loaded Nanostructured Lipid Carrier in 4T1-Induced Breast Cancer Mouse Model
Noraini Nordin et al.
MOLECULES (2020)
The dawn of targeted therapies for triple negative breast cancer (TNBC): a snapshot of investigational drugs in phase I and II trials
My-my Huynh et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2020)
The high cost of prescription drugs: causes and solutions
S. Vincent Rajkumar
BLOOD CANCER JOURNAL (2020)
Triple-negative breast cancer therapy: Current and future perspectives (Review)
Kwang-Ai Won et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2020)
A review of nanotechnology-based approaches for breast cancer and triple-negative breast cancer
Vikas Jain et al.
JOURNAL OF CONTROLLED RELEASE (2020)
Progress: Targeted Therapy, Immunotherapy, New Chemotherapy Strategies in Advanced Triple-Negative Breast Cancer
Jinhong Shi et al.
CANCER MANAGEMENT AND RESEARCH (2020)
Assessing the nanotechnology on the grounds of costs, benefits, and risks
Garima Pandey et al.
BENI-SUEF UNIVERSITY JOURNAL OF BASIC AND APPLIED SCIENCES (2020)
Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer
Ana C. Garrido-Castro et al.
BREAST CANCER RESEARCH (2020)
Improved therapeutic efficacy of quercetin-loaded polymeric nanoparticles on triple-negative breast cancer by inhibiting uPA
Yang Zhou et al.
RSC ADVANCES (2020)
Polymeric micelles for anticancer drug delivery
Nairrita Majumder et al.
THERAPEUTIC DELIVERY (2020)
Triple-negative breast cancer molecular subtyping and treatment progress
Li Yin et al.
BREAST CANCER RESEARCH (2020)
Nanosoldiers: A promising strategy to combat triple negative breast cancer
Akshayya Pawar et al.
BIOMEDICINE & PHARMACOTHERAPY (2019)
Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies
Yi-Zhou Jiang et al.
CANCER CELL (2019)
Multi-Omics Profiling Reveals Distinct Microenvironment Characterization and Suggests Immune Escape Mechanisms of Triple-Negative Breast Cancer
Yi Xiao et al.
CLINICAL CANCER RESEARCH (2019)
Efficacy of a novel LyP-1-containing self-microemulsifying drug delivery system (SMEDDS) for active targeting to breast cancer
Selin S. Timur et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2019)
Alginate lyase immobilized chitosan nanoparticles of ciprofloxacin for the improved antimicrobial activity against the biofilm associated mucoid P. aeruginosa infection in cystic fibrosis
Krishna Kumar Patel et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2019)
Targeted Lipid Nanoemulsions Encapsulating Epigenetic Drugs Exhibit Selective Cytotoxicity on CDH1-/FOXM1+ Triple Negative Breast Cancer Cells
Bumjun Kim et al.
MOLECULAR PHARMACEUTICS (2019)
Recent therapeutic trends and promising targets in triple negative breast cancer
Soo-Yeon Hwang et al.
PHARMACOLOGY & THERAPEUTICS (2019)
Application of Solid Lipid Nanoparticles to Improve the Efficiency of Anticancer Drugs
Laura Bayon-Cordero et al.
NANOMATERIALS (2019)
Effect of penetration enhancers and amorphization on transdermal permeation flux of raloxifene-encapsulated solid lipid nanoparticles: an ex vivo study on human skin
Krishna Kumar Patel et al.
APPLIED NANOSCIENCE (2019)
Nanosized functional miRNA liposomes and application in the treatment of TNBC by silencing Slug gene
Yan Yan et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2019)
Dendrimer mediated targeting of siRNA against polo-like kinase for the treatment of triple negative breast cancer
Anjali Jain et al.
JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A (2019)
Efficacy and safety of anti-PD-1 antibody SHR-1210 combined with apatinib in patients with advanced triple-negative breast cancer.
Jieqiong Liu et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Dora: A randomized phase II multicenter maintenance study of olaparib alone or olaparib in combination with durvalumab in platinum responsive advanced triple-negative breast cancer (aTNBC).
Sarah Sammons et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
An Ex Vivo Evaluation of Moxifloxacin Nanostructured Lipid Carrier Enriched In Situ Gel for Transcorneal Permeation on Goat Cornea
Shilpkala Gade et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2019)
Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial
Leonie Voorwerk et al.
NATURE MEDICINE (2019)
Talazoparib Loaded Solid Lipid Nanoparticles: Preparation, Characterization and Evaluation of the Therapeutic Efficacy In Vitro
Gamze Guney Eskiler et al.
CURRENT DRUG DELIVERY (2019)
Advances in Targeted Therapies for Triple-Negative Breast Cancer
Kelly E. McCann et al.
DRUGS (2019)
Cost-effectiveness of nanomedicine: estimating the real size of nano-costs
Rita Bosetti et al.
NANOMEDICINE (2019)
Current Applications of Nanoemulsions in Cancer Therapeutics
Elena Sanchez-Lopez et al.
NANOMATERIALS (2019)
Notch Signaling Activation as a Hallmark for Triple-Negative Breast Cancer Subtype
M. V. Giuli et al.
JOURNAL OF ONCOLOGY (2019)
Dimeric c(RGD) peptide conjugated nanostructured lipid carriers for efficient delivery of Gambogic acid to breast cancer
Dereje Kebebe et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2019)
Antibiofilm Potential of Silver Sulfadiazine-Loaded Nanoparticle Formulations: A Study on the Effect of DNase-I on Microbial Biofilm and Wound Healing Activity
Krishna Kumar Patel et al.
MOLECULAR PHARMACEUTICS (2019)
Recent advances in nanotheranostics for triple negative breast cancer treatment
Vikram Thakur et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Engineering Nanoparticles for Targeted Delivery of Nucleic Acid Therapeutics in Tumor
Yao Xiao et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2019)
Smart cancer nanomedicine
Roy van der Meel et al.
NATURE NANOTECHNOLOGY (2019)
Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy
J. H. Park et al.
ANNALS OF ONCOLOGY (2019)
Formulation-optimization of solid lipid nanocarrier system of STAT3 inhibitor to improve its activity in triple negative breast cancer cells
Sai Kiran S. S. Pindiprolu et al.
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY (2019)
PD-L1: an unavoidable biomarker in advanced triple-negative breast cancer
Mira Akiki et al.
BIOMARKERS IN MEDICINE (2019)
Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers
Sherene Loi et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Polyglutamic Acid Functionalization of Chitosan Nanoparticles Enhances the Therapeutic Efficacy of Insulin Following Oral Administration
Dileep Urimi et al.
AAPS PHARMSCITECH (2019)
Novel therapeutic avenues in triple-negative breast cancer: PI3K/AKT inhibition, androgen receptor blockade, and beyond
Jack J. Chan et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2019)
Improved tumor targeting and penetration by a dual-functional poly(amidoamine) dendrimer for the therapy of triple-negative breast cancer
Changliang Liu et al.
JOURNAL OF MATERIALS CHEMISTRY B (2019)
Fabrication of curcumin-loaded folic acid-tagged metal organic framework for triple negative breast cancer therapy in in vitro and in vivo systems
Dipranjan Laha et al.
NEW JOURNAL OF CHEMISTRY (2019)
Silver nanoparticles selectively treat triple-negative breast cancer cells without affecting non-malignant breast epithelial cells in vitro and in vivo
Jessica Swanner et al.
FASEB BIOADVANCES (2019)
An initial safety study of gedatolisib plus PTK7-ADC for metastatic triple-negative breast cancer
M. Radovich et al.
CANCER RESEARCH (2019)
Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple-Negative Breast Cancer
Hui Liu et al.
CANCER DISCOVERY (2018)
RAGE receptor targeted bioconjuguate lipid nanoparticles of diallyl disulfide for improved apoptotic activity in triple negative breast cancer: in vitro studies
Venkata Talluri Siddhartha et al.
ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY (2018)
Co-delivery of docetaxel and gemcitabine by anacardic acid modified self-assembled albumin nanoparticles for effective breast cancer management
Varun Kushwah et al.
ACTA BIOMATERIALIA (2018)
Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review
Ricardo L. B. Costa et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Alarming Burden of Triple-Negative Breast Cancer in India
Krishan K. Thakur et al.
CLINICAL BREAST CANCER (2018)
Androgen receptor expression is a favorable prognostic factor in triple-negative breast cancers
Tao Zuo et al.
HUMAN PATHOLOGY (2018)
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial
Sibylle Loibl et al.
LANCET ONCOLOGY (2018)
Co-delivery of docetaxel and gemcitabine using PEGylated self-assembled stealth nanoparticles for improved breast cancer therapy
Varun Kushwah et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2018)
Liposomal Irinotecan Accumulates in Metastatic Lesions, Crosses the Blood-Tumor Barrier (BTB), and Prolongs Survival in an Experimental Model of Brain Metastases of Triple Negative Breast Cancer
Afroz S. Mohammad et al.
PHARMACEUTICAL RESEARCH (2018)
Cancer immunotherapy using checkpoint blockade
Antoni Ribas et al.
SCIENCE (2018)
Metastatic and triple-negative breast cancer: challenges and treatment options
Sumayah Al-Mahmood et al.
DRUG DELIVERY AND TRANSLATIONAL RESEARCH (2018)
Molecular Mechanisms and Emerging Therapeutic Targets of Triple-Negative Breast Cancer Metastasis
Christiana Neophytou et al.
FRONTIERS IN ONCOLOGY (2018)
From design to the clinic: practical guidelines for translating cardiovascular nanomedicine
Iwona Cicha et al.
CARDIOVASCULAR RESEARCH (2018)
Improved antitumor efficacy and reduced toxicity of docetaxel using anacardic acid functionalized stealth liposomes
Varun Kushwah et al.
COLLOIDS AND SURFACES B-BIOINTERFACES (2018)
TOPACIO/Keynote-162 (NCT02657889): A phase 1/2 study of niraparib plus pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC)-Results from ROC cohort.
Panagiotis A. Konstantinopoulos et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
PARTNER: Randomised, phase II/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients.
Jean Abraham et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial
Peter Schmid et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Epirubicin-loaded polymeric micelles effectively treat axillary lymph nodes metastasis of breast cancer through selective accumulation and pH-triggered drug release
Tsukasa Chida et al.
JOURNAL OF CONTROLLED RELEASE (2018)
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
P. Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Nanoemulsion-Enabled Oral Delivery of Novel Anticancer ω-3 Fatty Acid Derivatives
Gabriela Garrastazu Pereira et al.
NANOMATERIALS (2018)
Cisplatin Loaded Multiwalled Carbon Nanotubes Induce Resistance in Triple Negative Breast Cancer Cells
Madalina Andreea Badea et al.
PHARMACEUTICS (2018)
Thymoquinone loaded in nanostructured lipid carrier showed enhanced anticancer activity in 4T1 tumor-bearing mice
Yong Sze Ong et al.
NANOMEDICINE (2018)
Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems: applications, advantages and disadvantages
Parisa Ghasemiyeh et al.
RESEARCH IN PHARMACEUTICAL SCIENCES (2018)
Metastatic triple negative breast cancer: Optimizing treatment options, new and emerging targeted therapies
Parham Khosravi-Shahi et al.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2018)
How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies
Ji Hyun Park et al.
ESMO OPEN (2018)
PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer
Jill J. J. Geenen et al.
CLINICAL PHARMACOKINETICS (2018)
Docetaxel and cyclophosphamide as neoadjuvant chemotherapy in HER2-negative primary breast cancer
Katsuhiko Nakatsukasa et al.
BREAST CANCER (2017)
Phase I study of the gamma secretase inhibitor PF-03084014 in combination with docetaxel in patients with advanced triple-negative breast cancer
Marzia A. Locatelli et al.
ONCOTARGET (2017)
Enhanced apoptotic and anticancer potential of paclitaxel loaded biodegradable nanoparticles based on chitosan
Umesh Gupta et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES (2017)
Styrene maleic acid-encapsulated RL71 micelles suppress tumor growth in a murine xenograft model of triple negative breast cancer
Orleans Martey et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2017)
Sequential delivery of erlotinib and doxorubicin for enhanced triple negative Breast cancer treatment using polymeric nanoparticle
Zilan Zhou et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2017)
Blood-brain barrier-penetrating amphiphilic polymer nanoparticles deliver docetaxel for the treatment of brain metastases of triple negative breast cancer
Chunsheng He et al.
JOURNAL OF CONTROLLED RELEASE (2017)
α-Tocopherol as functional excipient for resveratrol and coenzyme Q10-loaded SNEDDS for improved bioavailability and prophylaxis of breast cancer
Sanyog Jain et al.
JOURNAL OF DRUG TARGETING (2017)
Lipid Based nanoformulation of lycopene improves oral delivery: formulation optimization, ex vivo assessment and its efficacy against breast cancer
Archu Singh et al.
JOURNAL OF MICROENCAPSULATION (2017)
Micellear Gold Nanoparticles as Delivery Vehicles for Dual Tyrosine Kinase Inhibitor ZD6474 for Metastatic Breast Cancer Treatment
Siddik Sarkar et al.
LANGMUIR (2017)
Dendrimers as Nanocarriers for Nucleic Acid and Drug Delivery in Cancer Therapy
Livia Palmerston Mendes et al.
MOLECULES (2017)
Anticancer Effects of Resveratrol-Loaded Solid Lipid Nanoparticles on Human Breast Cancer Cells
Wenrui Wang et al.
MOLECULES (2017)
Milk-derived exosomes for oral delivery of paclitaxel
Ashish K. Agrawal et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2017)
Elements of cancer immunity and the cancer-immune set point
Daniel S. Chen et al.
NATURE (2017)
The multifaceted roles of PARP1 in DNA repair and chromatin remodelling
Arnab Ray Chaudhuri et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2017)
Improved Stability and Enhanced Oral Bioavailability of Atorvastatin Loaded Stearic Acid Modified Gelatin Nanoparticles
Deepanshu Shilpi et al.
PHARMACEUTICAL RESEARCH (2017)
Triple-negative breast cancer and the potential for targeted therapy
Jing-Ru Jhan et al.
PHARMACOGENOMICS (2017)
Brain-derived neurotrophic factor (BDNF) - TrKB signaling modulates cancer-endothelial cells interaction and affects the outcomes of triple negative breast cancer
Yi-Fang Tsai et al.
PLOS ONE (2017)
LOXL4 knockdown enhances tumor growth and lung metastasis through collagen-dependent extracellular matrix changes in triple-negative breast cancer
Sul Ki Choi et al.
ONCOTARGET (2017)
Potential therapeutic targets of triple-negative breast cancer based on its intrinsic subtype
Fangyuan Shao et al.
ONCOTARGET (2017)
Stimuli-Responsive Mesoporous Silica NPs as Non-viral Dual siRNA/Chemotherapy Carriers for Triple Negative Breast Cancer
Behrad Darvishi et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2017)
Phase II trial of pembrolizumab in combination with nab-paclitaxel in patients with metastatic HER2-negative breast cancer
Maryann J. Kwa et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Clinical application of polymeric micelles for the treatment of cancer
Aida Varela-Moreira et al.
MATERIALS CHEMISTRY FRONTIERS (2017)
Androgen receptor in estrogen receptor positive breast cancer: Beyond expression
Debora Basile et al.
CANCER TREATMENT REVIEWS (2017)
Exosomes for the Enhanced Tissue Bioavailability and Efficacy of Curcumin
Farrukh Aqil et al.
AAPS JOURNAL (2017)
A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67
Bojana Jovanovic et al.
CLINICAL CANCER RESEARCH (2017)
NCT02456857: A phase II trial of liposomal doxorubicin, bevacizumab and everolimus (DAE) in patients with localized triple-negative breast cancer (TNBC) with tumors predicted insensitive to standard neoadjuvant chemotherapy
Senthil Damodaran et al.
CANCER RESEARCH (2017)
Dual-targeted hybrid nanoparticles of synergistic drugs for treating lung metastases of triple negative breast cancer in mice
Tian Zhang et al.
ACTA PHARMACOLOGICA SINICA (2017)
Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects
Hongyan Jia et al.
DRUG RESISTANCE UPDATES (2017)
Honokiol nanomicellar formulation produced increased oral bioavailability and anticancer effects in triple negative breast cancer (TNBC)
Chandraiah Godugu et al.
COLLOIDS AND SURFACES B-BIOINTERFACES (2017)
Triple-negative first-line study: Neoadjuvant trial of nab-paclitaxel and atezolizumab, a PD-L1 inhibitor, in patients with triple negative breast cancer (TNBC) (NCT02530489)
J. K. Litton et al.
CANCER RESEARCH (2017)
PIQHASSO: Open label, non-randomized, multicenter phase 1/2b study investigating safety and efficacy of PQR309 and eribulin combination in patients (pts) with locally advanced (LA) or metastatic HER2 (-) and triple-negative breast cancer (TNBC) (study PQR309-007)
E. Lopez-Miranda et al.
CANCER RESEARCH (2017)
Biological Subtypes of Triple-Negative Breast Cancer
Michael Hubalek et al.
BREAST CARE (2017)
Tumor neovasculature-targeted cationic PEGylated liposomes of gambogic acid for the treatment of triple-negative breast cancer
Ravi Doddapaneni et al.
DRUG DELIVERY (2016)
Folate Receptor-Targeted Polymeric Micellar Nanocarriers for Delivery of Orlistat as a Repurposed Drug against Triple-Negative Breast Cancer
Ramasamy Paulmurugan et al.
MOLECULAR CANCER THERAPEUTICS (2016)
A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1)
H. Bonnefoi et al.
ANNALS OF ONCOLOGY (2016)
Blood-Brain Barrier and Breast Cancer Resistance Protein: A Limit to the Therapy of CNS Tumors and Neurodegenerative Diseases
Anna Lisa Iorio et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2016)
Integration of photothermal therapy and synergistic chemotherapy by a porphyrin self-assembled micelle confers chemosensitivity in triple-negative breast cancer
Shishuai Su et al.
BIOMATERIALS (2016)
Aminoflavone-loaded EGFR-targeted unimolecular micelle nanoparticles exhibit anti-cancer effects in triple negative breast cancer
Ashley M. Brinkman et al.
BIOMATERIALS (2016)
Selective activity of deguelin identifies therapeutic targets for androgen receptor-positive breast cancer
Andrew J. Robles et al.
BREAST CANCER RESEARCH AND TREATMENT (2016)
Androgen receptor signaling pathways as a target for breast cancer treatment
Elisabetta Pietri et al.
ENDOCRINE-RELATED CANCER (2016)
Novel diindolylmethane derivatives based NLC formulations to improve the oral bioavailability and anticancer effects in triple negative breast cancer
Chandraiah Godugu et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2016)
PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas
Ashley Cimino-Mathews et al.
HUMAN PATHOLOGY (2016)
Nanomedicines for advanced cancer treatments: Transitioning towards responsive systems
Merel van Elk et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2016)
Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors
Patricia Mucci LoRusso
JOURNAL OF CLINICAL ONCOLOGY (2016)
Features of triple-negative breast cancer: Analysis of 38,813 cases from the national cancer database
Magdalena L. Plasilova et al.
MEDICINE (2016)
Abstract B05: Self-assembling platinum-acridine loaded carbon nanotubes for triple-negative breast cancer chemotherapy
Cale D. Fahrenholtz et al.
MOLECULAR CANCER RESEARCH (2016)
The hedgehog pathway in triple-negative breast cancer
Joyce G. Habib et al.
CANCER MEDICINE (2016)
Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes A Systematic Review
Sasha E. Stanton et al.
JAMA ONCOLOGY (2016)
Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection
Brian D. Lehmann et al.
PLOS ONE (2016)
Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer
Yi-Rong Liu et al.
BREAST CANCER RESEARCH (2016)
Mammalian Target of Rapamycin: Its Role in Early Neural Development and in Adult and Aged Brain Function
Carla Garza-Lombo et al.
FRONTIERS IN CELLULAR NEUROSCIENCE (2016)
Triple-negative breast cancer: treatment challenges and solutions
Joelle Collignon et al.
BREAST CANCER-TARGETS AND THERAPY (2016)
Chitosan layered gold nanorods as synergistic therapeutics for photothermal ablation and gene silencing in triple-negative breast cancer
Zhizhou Yang et al.
ACTA BIOMATERIALIA (2015)
Targeted Therapies in Triple-Negative Breast Cancer
Frederik Marme et al.
BREAST CARE (2015)
Therapeutic targets of triple-negative breast cancer: a review
Vinayak S. Jamdade et al.
BRITISH JOURNAL OF PHARMACOLOGY (2015)
A phase II study of capecitabine plus cisplatin in metastatic triple-negative breast cancer patients pretreated with anthracyclines and taxanes
Qiao Li et al.
CANCER BIOLOGY & THERAPY (2015)
The Inositol Polyphosphate 5-Phosphatase PIPP Regulates AKT1-Dependent Breast Cancer Growth and Metastasis
Lisa M. Ooms et al.
CANCER CELL (2015)
Albumin-bound nanoparticle (nab) paclitaxel exhibits enhanced paclitaxel tissue distribution and tumor penetration
Nianhang Chen et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
Notch signaling: An emerging therapeutic target for cancer treatment
Xun Yuan et al.
CANCER LETTERS (2015)
Silencing β3 Integrin by Targeted ECO/siRNA Nanoparticles Inhibits EMT and Metastasis of Triple-Negative Breast Cancer
Jenny G. Parvani et al.
CANCER RESEARCH (2015)
First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer
Geoffrey I. Shapiro et al.
CLINICAL CANCER RESEARCH (2015)
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy
Edgar Perez-Herrero et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2015)
Polymeric nanoparticles for targeted treatment in oncology: current insights
Rashmi H. Prabhu et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2015)
Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2-Positive and Triple-Negative Primary Breast Cancers
Carsten Denkert et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Anti-migratory and increased cytotoxic effects of novel dual drug-loaded complex hybrid micelles in triple negative breast cancer cells
Rajaletchumy Veloo Kutty et al.
NANO RESEARCH (2015)
Development of dual toxoid-loaded layersomes for complete immunostimulatory response following peroral administration
Harshad Harde et al.
NANOMEDICINE (2015)
Clinical and molecular complexity of breast cancer metastases
Siker Kimbung et al.
SEMINARS IN CANCER BIOLOGY (2015)
The role of taxanes in triple-negative breast cancer: literature review
Giorgio Mustacchi et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2015)
Application of functional vincristine plus dasatinib liposomes to deletion of vasculogenic mimicry channels in triple-negative breast cancer
Fan Zeng et al.
ONCOTARGET (2015)
Subtyping of Triple-Negative Breast Cancer: Implications for Therapy
Vandana G. Abramson et al.
CANCER (2015)
Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer
Matthew D. Burstein et al.
CLINICAL CANCER RESEARCH (2015)
Cisplatin and gemcitabine as the first line therapy in metastatic triple negative breast cancer
Jian Zhang et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
BRCA1 regulation of epidermal growth factor receptor (EGFR) expression in human breast cancer cells involves microRNA-146a and is critical for its tumor suppressor function
E. Kumaraswamy et al.
ONCOGENE (2015)
Analysis of PIK3CA Mutations and Activation Pathways in Triple Negative Breast Cancer
Paolo Cossu-Rocca et al.
PLOS ONE (2015)
Development of a topical adapalene-solid lipid nanoparticle loaded gel with enhanced efficacy and improved skin tolerability
Harshad Harde et al.
RSC ADVANCES (2015)
A Multifunctional Polymeric Nanotheranostic System Delivers Doxorubicin and Imaging Agents across the Blood-Brain Barrier Targeting Brain Metastases of Breast Cancer
Jason Li et al.
ACS NANO (2014)
Improved Stability and Antidiabetic Potential of Insulin Containing Folic Acid Functionalized Polymer Stabilized Multi layered Liposomes Following Oral Administration
Ashish Kumar Agrawal et al.
BIOMACROMOLECULES (2014)
Programmed Cell Death 1 (PD-1) and Its Ligand (PD-L1) in Common Cancers and Their Correlation with Molecular Cancer Type
Zoran Gatalica et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2014)
Transient SNAIL1 Expression Is Necessary for Metastatic Competence in Breast Cancer
Hung D. Tran et al.
CANCER RESEARCH (2014)
Triple-negative breast cancer: molecular subtypes and targeted therapy
Kim M. Hirshfield et al.
CURRENT OPINION IN OBSTETRICS & GYNECOLOGY (2014)
Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199
Sylvia Adams et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
An investigation of in vivo wound healing activity of biologically synthesized silver nanoparticles
Abhishek Kaler et al.
JOURNAL OF NANOPARTICLE RESEARCH (2014)
Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes
Brian D. Lehmann et al.
JOURNAL OF PATHOLOGY (2014)
US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status
Nadia Howlader et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
High EGFR gene copy number predicts poor outcome in triple-negative breast cancer
Heae Surng Park et al.
MODERN PATHOLOGY (2014)
Nanoparticles for gene delivery: therapeutic and toxic effects
Young Suk Choi et al.
MOLECULAR & CELLULAR TOXICOLOGY (2014)
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial
Gunter von Minckwitz et al.
LANCET ONCOLOGY (2014)
Combinatorial bio-conjugation of gemcitabine and curcumin enables dual drug delivery with synergistic anticancer efficacy and reduced toxicity
Sanyog Jain et al.
RSC ADVANCES (2014)
Carbon nanotubes: properties, synthesis, purification, and medical applications
Ali Eatemadi et al.
NANOSCALE RESEARCH LETTERS (2014)
PD-L1 Expression in Triple-Negative Breast Cancer
Elizabeth A. Mittendorf et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Suppression of Invasion and Metastasis of Triple-Negative Breast Cancer Lines by Pharmacological or Genetic Inhibition of Slug Activity
Giovanna Ferrari-Amorotti et al.
NEOPLASIA (2014)
Molecular Heterogeneity of Triple-Negative Breast Cancer
Vandana G. Abramson et al.
CURRENT BREAST CANCER REPORTS (2014)
A randomized, parallel-arm, phase H trial to assess the efficacy of preoperative ixahepilone with or without cetuximab in patients with triple-negative breast cancer (TNBC).
Angel Augusto Rodriguez et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Severe and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer
Rachel M. Layman et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes
Hiroko Masuda et al.
CLINICAL CANCER RESEARCH (2013)
Establishment of a 5-fluorouracil-resistant triple-negative breast cancer cell line
Katsuyuki Takahashi et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2013)
Surface Stabilized Efavirenz Nanoparticles for Oral Bioavailability Enhancement
Sanyog Jain et al.
JOURNAL OF BIOMEDICAL NANOTECHNOLOGY (2013)
TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer
Neil E. Bhola et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Therapeutic targets in triple negative breast cancer
Sandra A. O'Toole et al.
JOURNAL OF CLINICAL PATHOLOGY (2013)
Combined Targeting of mTOR and AKT Is an Effective Strategy for Basal-like Breast Cancer in Patient-Derived Xenograft Models
Siguang Xu et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Enhanced Transfection Efficiency and Reduced Cytotoxicity of Novel Lipid-Polymer Hybrid Nanoplexes
Sanyog Jain et al.
MOLECULAR PHARMACEUTICS (2013)
Luteolin is a novel p90 ribosomal S6 kinase (RSK) inhibitor that suppresses Notch4 signaling by blocking the activation of Y-box binding protein-1 (YB-1)
Kristen M. Reipas et al.
ONCOTARGET (2013)
Carbon Nanotubes: Applications in Pharmacy and Medicine
Hua He et al.
BIOMED RESEARCH INTERNATIONAL (2013)
The Potential Role of Nanotechnology in Therapeutic Approaches for Triple Negative Breast Cancer
Rebecca Johnson et al.
Pharmaceutics (2013)
Regulatory networks defining EMT during cancer initiation and progression
Bram De Craene et al.
NATURE REVIEWS CANCER (2013)
Triple-negative breast cancer in the older population
P. Boyle
ANNALS OF ONCOLOGY (2012)
The diverse roles and clinical relevance of PARPs in DNA damage repair: Current state of the art
Mike De Vos et al.
BIOCHEMICAL PHARMACOLOGY (2012)
Developmental pathways in breast cancer and breast tumor-initiating cells: Therapeutic implications
Julia Izrailit et al.
CANCER LETTERS (2012)
mTOR inhibitors in cancer therapy
Yekaterina Y. Zaytseva et al.
CANCER LETTERS (2012)
Src kinases catalytic activity regulates proliferation, migration and invasiveness of MDA-MB-231 breast cancer cells
Maria Pilar Sanchez-Bailon et al.
CELLULAR SIGNALLING (2012)
Toxicological considerations when creating nanoparticle-based drugs and drug delivery systems
Arati Sharma et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2012)
Notch-1 and Notch-4 Biomarker Expression in Triple-Negative Breast Cancer
Jodi Speiser et al.
INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY (2012)
The Upcoming Field of Theranostic Nanomedicine: An Overview
Priyanka Prabhu et al.
JOURNAL OF BIOMEDICAL NANOTECHNOLOGY (2012)
The wnt/beta-catenin signaling pathway: A potential therapeutic target in the treatment of triple negative breast cancer
Taj D. King et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2012)
Doxil® - The first FDA-approved nano-drug: Lessons learned
Yechezkel (Chezy) Barenholz
JOURNAL OF CONTROLLED RELEASE (2012)
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt et al.
NATURE (2012)
Molecular Basis of Triple Negative Breast Cancer and Implications for Therapy
Parvin F. Peddi et al.
INTERNATIONAL JOURNAL OF BREAST CANCER (2012)
Src: a potential target for the treatment of triple-negative breast cancer
D. Tryfonopoulos et al.
ANNALS OF ONCOLOGY (2011)
Role of Notch and its oncogenic signaling crosstalk in breast cancer
Shanchun Guo et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2011)
Functional Characterization of an scFv-Fc Antibody that Immunotherapeutically Targets the Common Cancer Cell Surface Proteoglycan CSPG4
Xinhui Wang et al.
CANCER RESEARCH (2011)
Phase II Trial of Saracatinib (AZD0530), an Oral SRC-inhibitor for the Treatment of Patients with Hormone Receptor-negative Metastatic Breast Cancer
Ayca Gucalp et al.
CLINICAL BREAST CANCER (2011)
Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer
Ana M. Gonzalez-Angulo et al.
CLINICAL CANCER RESEARCH (2011)
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
Brian D. Lehmann et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Invasive Breast Cancer
Robert W. Carlson et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2011)
TOXICOLOGY OF NANOMATERIALS USED IN NANOMEDICINE
Jinshun Zhao et al.
JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH-PART B-CRITICAL REVIEWS (2011)
β-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation
Felipe C. Geyer et al.
MODERN PATHOLOGY (2011)
Combinatorial Effects of Lapatinib and Rapamycin in Triple-Negative Breast Cancer Cells
Tongrui Liu et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Niclosamide Suppresses Cancer Cell Growth By Inducing Wnt Co-Receptor LRP6 Degradation and Inhibiting the Wnt/β-Catenin Pathway
Wenyan Lu et al.
PLOS ONE (2011)
Numb protein expression correlates with a basal-like phenotype and cancer stem cell markers in primary breast cancer
Karin Rennstam et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Targeting Hedgehog - a Cancer Stem Cell Pathway
Akil A. Merchant et al.
CLINICAL CANCER RESEARCH (2010)
New Insights of CTLA-4 into Its Biological Function in Breast Cancer
H. Mao et al.
CURRENT CANCER DRUG TARGETS (2010)
CSPG4 in Cancer: Multiple Roles
X. Wang et al.
CURRENT MOLECULAR MEDICINE (2010)
PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality
Elena Lopez-Knowles et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer
Carsten Denkert et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials
Nicolai Juul et al.
LANCET ONCOLOGY (2010)
Notch1-induced mammary tumor development is cyclin D1-dependent and correlates with expansion of pre-malignant multipotent duct-limited progenitors
H. Ling et al.
ONCOGENE (2010)
Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer
Maura N. Dickler et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Biology, Metastatic Patterns, and Treatment of Patients with Triple-Negative Breast Cancer
Carey K. Anders et al.
CLINICAL BREAST CANCER (2009)
Decreased levels of UMP kinase as a mechanism of fluoropyrimidine resistance
Rita Humeniuk et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Base Excision by Thymine DNA Glycosylase Mediates DNA-Directed Cytotoxicity of 5-Fluorouracil
Christophe Kunz et al.
PLOS BIOLOGY (2009)
Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes
Olafur Andri Stefansson et al.
BREAST CANCER RESEARCH (2009)
PD-1 and its ligands in tolerance and immunity
Mary E. Keir et al.
ANNUAL REVIEW OF IMMUNOLOGY (2008)
Sites of Distant Recurrence and Clinical Outcomes in Patients With Metastatic Triple-negative Breast Cancer High Incidence of Central Nervous System Metastases
Nancy U. Lin et al.
CANCER (2008)
Opposite Effects of Notch-1 and Notch-2 on Mesothelioma Cell Survival under Hypoxia Are Exerted through the Akt Pathway
Irene Graziani et al.
CANCER RESEARCH (2008)
The epithelial-mesenchymal transition generates cells with properties of stem cells
Sendurai A. Mani et al.
CELL (2008)
Genetic changes of Wnt pathway genes are common events in metaplastic carcinomas of the breast
Michael J. Hayes et al.
CLINICAL CANCER RESEARCH (2008)
Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes
Christine Desmedt et al.
CLINICAL CANCER RESEARCH (2008)
The molecular logic of Notch signaling - a structural and biochemical perspective
Wendy R. Gordon et al.
JOURNAL OF CELL SCIENCE (2008)
More complicated than it looks: assembly of Notch pathway transcription complexes
R. A. Kovall
ONCOGENE (2008)
Hedgehog signaling, epithelial-to-mesenchymal transition and miRNA (Review)
Yuriko Katoh et al.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2008)
Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/triple-negative'' breast cancer cell lines growing in vitro
Richard S. Finn et al.
BREAST CANCER RESEARCH AND TREATMENT (2007)
Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients - A single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results Database
Gloria J. Morris et al.
CANCER (2007)
ErbB receptors: from oncogenes to targeted cancer therapies
Hongtao Zhang et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Triple-negative breast cancer: Clinical features and patterns of recurrence
Rebecca Dent et al.
CLINICAL CANCER RESEARCH (2007)
Medulloblastoma: tumorigenesis, current clinical paradigm, and efforts to improve risk stratification
William R. Polkinghorn et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2007)
Notch signaling, gamma-secretase inhibitors, and cancer therapy
Ie-Ming Shih et al.
CANCER RESEARCH (2007)
Curcumin inhibits the mammalian target of rapamycin-mediated signaling pathways in cancer cells
Christopher S. Beevers et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Hedgehog signaling and response to cyclopamine differ in epithelial and stromal cells in benign breast and breast cancer
Shibani Mukherjee et al.
CANCER BIOLOGY & THERAPY (2006)
Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers
Francois Bertucci et al.
CANCER RESEARCH (2006)
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Nicastrin functions as a γ-secretase-substrate receptor
S Shah et al.
CELL (2005)
Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer
J Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Chemopotentiation by PARP inhibitors in cancer therapy
L Tentori et al.
PHARMACOLOGICAL RESEARCH (2005)
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
The promoters of human cell cycle genes integrate signals from two tumor suppressive pathways during cellular transformation
Yuval Tabach et al.
MOLECULAR SYSTEMS BIOLOGY (2005)
A putative human breast stem cell population is enriched for steroid receptor-positive cells
RB Clarke et al.
DEVELOPMENTAL BIOLOGY (2005)
Novel chemical strategies for thymidylate synthase inhibition
WH Gmeiner
CURRENT MEDICINAL CHEMISTRY (2005)
Mammary stem cells, self-renewal pathways, and carcinogenesis
SL Liu et al.
BREAST CANCER RESEARCH (2005)
A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer
G von Minckwitz et al.
BREAST CANCER RESEARCH AND TREATMENT (2005)
Next stop, the twilight zone: Hedgehog network regulation of mammary gland development
MT Lewis et al.
JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA (2004)
Effects of novel inhibitors of poly(ADP-ribose) polymerase-1 and the DNA-dependent protein kinase on enzyme activities and DNA repair
SJ Veuger et al.
ONCOGENE (2004)
Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis
J Yang et al.
CELL (2004)
Review of epidermal growth factor receptor biology
RS Herbst
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2004)
Loss of negative regulation by Numb over Notch is relevant to human breast carcinogenesis
S Pece et al.
JOURNAL OF CELL BIOLOGY (2004)
Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells
G Dontu et al.
BREAST CANCER RESEARCH (2004)
Protein kinase Cα negatively regulates cell spreading and motility in MDA-MB-231 human breast cancer cells downstream of epidermal growth factor receptor
ML Gauthier et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2003)
Molecular portraits of human breast tumours
CM Perou et al.
NATURE (2000)
Confirmation of the mapping of the Camurati-Englemann locus to 19q13.2 and refinement to a 3.2-cM region
SP Vaughn et al.
GENOMICS (2000)
A novel proteolytic cleavage involved in Notch signaling:: The role of the disintegrin-metalloprotease TACE
C Brou et al.
MOLECULAR CELL (2000)
A ligand-induced extracellular cleavage regulates γ-secretase-like proteolytic activation of Notch1
JS Mumm et al.
MOLECULAR CELL (2000)
Genetic mapping of the Camurati-Engelmann disease locus to chromosome 19q13.1-q13.3
M Ghadami et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2000)
分享论文
